Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Hengrui Pharmaceuticals (01276.HK) Subsidiary's HRS-7156 Tablets Approved for Clinical Trial
Recommend 4 Positive 8 Negative 1 |
||||
|
||||
|
Hengrui Pharmaceuticals (01276.HK) (600276.SH) announced that the clinical trial application for HRS-7156 tablets developed by its subsidiary Shandong Shengdi has been approved by the National Medical Products Administration. The proposed indication is heart failure. HRS-7156 tablets are a Class 1 innovative drug independently developed by the company, with cumulative research and development investment amounting to approximately RMB37.6 million to date. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
